ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma

Aldehyde dehydrogenase 1A1 (ALDH1A1) is considered to be a cancer stem cell marker in several human malignancies. However, the role of ALDH1A1 in hepatocellular carcinoma (HCC) has not been well elucidated. In this study, we investigated the relationship between ALDH1A1 and clinicopathological findings and examined whether ALDH1A1 deserves to be a cancer stem cell marker in HCC. Sixty HCC samples obtained from surgical resection were collected for immunohistochemical (IHC) staining. Of these 60 samples, 47 samples of HCC tumorous and non-tumorous tissues were evaluated with qRT-PCR. There was no significant difference in the ALDH1A1-mRNA level between tumorous and non-tumorous tissues. Tumorous ALDH1A1-mRNA level had no relationship with the clinicopathological features. Immunoreactivity of ALDH1A1 was classified into two groups based on the percentage of ALDH1A1-overexpressing cells. The ALDH1A1-high group was significantly associated with low serum levels of α-fetoprotein, small tumor diameter, very little lymphovascular invasion, more differentiated pathology and good stage. The ALDH1A1-high group showed more favorable prognosis for recurrence-free survival. In double-staining IHC, ALDH1A1 was not co-expressed with BMI1, EpCAM, CD13, CD24, CD90 and CD133, which reported as cancer stem cell markers in HCC. In conclusion, ALDH1A1-overexpressing cells could appear to be differentiated cells rather than cancer stem cells in HCC.

[1]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[2]  J. Nolta,et al.  Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. , 2004, Blood.

[3]  Liver Cancer Study Group of Japan.  The general rules for the clinical and pathological study of primary liver cancer , 2006, The Japanese journal of surgery.

[4]  D. Bonnet,et al.  The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopoietic stem cells. , 2007, Experimental hematology.

[5]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[6]  C. Brocker,et al.  Non-P 450 aldehyde oxidizing enzymes : the aldehyde dehydrogenase superfamily , 2009 .

[7]  K. Chan,et al.  Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations , 2008, Molecular Cancer Research.

[8]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[9]  A. Iwama,et al.  The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. , 2008, Cancer research.

[10]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[11]  M. Zern,et al.  Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. , 2010, Experimental and molecular pathology.

[12]  K. Mimori,et al.  CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.

[13]  R. Bast,et al.  Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer , 2010, Molecular Cancer Therapeutics.

[14]  M. Koch,et al.  Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer , 2011, BMC Cancer.

[15]  Zhenqiu Liu,et al.  ALDH1A1 Is a Marker for Malignant Prostate Stem Cells and Predictor of Prostate Cancer Patients’ Outcome , 2009, Laboratory Investigation.

[16]  Hongxiang Liu,et al.  CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma , 2011, BMC Cancer.

[17]  K. Sugamura,et al.  Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines , 2010, Cancer science.

[18]  I. Ng,et al.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.

[19]  P. Marcato,et al.  Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform , 2011, Cell cycle.

[20]  D. Calvisi,et al.  Bmi1 Is Required for Hepatic Progenitor Cell Expansion and Liver Tumor Development , 2012, PloS one.

[21]  M. Koch,et al.  Expression Analysis of Aldehyde Dehydrogenase 1A1 (ALDH1A1) in Colon and Rectal Cancer in Association with Prognosis and Response to Chemotherapy , 2012, Annals of Surgical Oncology.

[22]  M. Miyazaki,et al.  Aldehyde dehydrogenase 1 is associated with recurrence‐free survival but not stem cell‐like properties in hepatocellular carcinoma , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  Vindhya Koppaka,et al.  Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application , 2012, Pharmacological Reviews.

[24]  V. Rogiers,et al.  Successful isolation of liver progenitor cells by aldehyde dehydrogenase activity in naïve mice , 2012, Hepatology.

[25]  E. Abamor,et al.  Aldehyde Dehydrogenase: Cancer and Stem Cells , 2012 .

[26]  T. Khoury,et al.  Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy , 2012, Modern Pathology.

[27]  Jiayin Yang,et al.  Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis , 2013, European journal of gastroenterology & hepatology.

[28]  P. Russell,et al.  The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer , 2013, Thorax.

[29]  K. Nan,et al.  Bmi1 knockdown inhibits hepatocarcinogenesis. , 2013, International journal of oncology.

[30]  You-hong Cui,et al.  ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis , 2014, BMC Cancer.

[31]  Q. Sun,et al.  Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse , 2013, Cancer Cell International.

[32]  Lei-bo Xu,et al.  Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil. , 2013, Oncology reports.

[33]  Xiang Fu,et al.  ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer , 2014, BMC Cancer.

[34]  Y. Liu,et al.  Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma. , 2014, International journal of clinical and experimental pathology.

[35]  Peng Zhang,et al.  ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma , 2014, Modern Pathology.

[36]  Honghao Li,et al.  High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma , 2014, World Journal of Surgical Oncology.